The Heart: A Novel Gonadotrophin-Releasing Hormone Target

Journal of Neuroendocrinology

Volumn 23, Issue 5, 2011, Pages 456-463

  Dong, F ^a   Skinner, D C ^b   John Wu, T ^c   Ren, J ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF WYOMING   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Cardiomyocyte shortening; GnRH; Intracellular Ca2+; PKA; PKC

Indexed keywords

CALCIUM ION; CETRORELIX; CHELERYTHRINE CHLORIDE; FURA 2; GONADORELIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BENZOPHENANTHRIDINES; CALCIUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; ISOQUINOLINES; MALE; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PROTEIN KINASE C; SULFONAMIDES;

EID: 79954545743     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2011.02119.x     Document Type: Article

References (72)

1. Tandler R, Kondruweit M, Fischlein T, Weyand M. Hormone therapy in men-increased risk of cardiac allograft rejection? J Heart Lung Transplant 2003; 22: 831.
2. Dockery F, Rajkumar C, Agarwal S, Waxman J, Bulpitt CJ. Androgen deprivation in males is associated with decreased central arterial compliance and reduced central systolic blood pressure. J Hum Hypertens 2000; 14: 395-397.
3. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104: 195-201.
4. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
5. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-2425.
6. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-1500.
7. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-1524.
8. Smith MR. Treatment-related diabetes and cardiovascular disease in prostate cancer survivors. Ann Oncol 2008; 19(Suppl 7): vii86-vii90.
9. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2009; 102: 1-8.
10. Schally AV, Meites J, Bowers CY, Ratner A. Identity of prolactin inhibiting factor (Pif) and luteinizing hormone-releasing factor (Lrf). Proc Soc Exp Biol Med 1964; 117: 252-254.
11. Wirsig-Wiechmann CR, Wiechmann AF. Vole retina is a target for gonadotropin-releasing hormone. Brain Res 2002; 950: 210-217.
12. Wirsig-Wiechmann CR. Function of gonadotropin-releasing hormone in olfaction. Keio J Med 2001; 50: 81-85.
13. Khan MA, Ferro VA, Stimson WH. Use of a highly specific monoclonal antibody against the central variable amino acid sequence of mammalian gonadotropin releasing hormone to evaluate GnRH-I tissue distribution compared with GnRH-I binding sites in adult male rats. Am J Reprod Immunol 2003; 49: 239-248.
14. Clayton RN, Eccleston L, Gossard F, Thalbard JC, Morel G. Rat granulosa cells express the gonadotrophin-releasing hormone gene: evidence from in-situ hybridization histochemistry. J Mol Endocrinol 1992; 9: 189-195.
15. Bahk JY, Hyun JS, Chung SH, Lee H, Kim MO, Lee BH, Choi WS. Stage specific identification of the expression of GnRH mRNA and localization of the GnRH receptor in mature rat and adult human testis. J Urol 1995; 154: 1958-1961.
16. Reichler I, Barth A, Piche C, Jochle W, Roos M, Hubler M, Arnold S. Urodynamic parameters and plasma LH/FSH in spayed Beagle bitches before and 8weeks after GnRH depot analogue treatment. Theriogenology 2006; 66: 2127-2136.
17. Reichler I, Hubler M, Jochle W, Trigg TE, Piche C, Arnold S. The effect of GnRH analogs on urinary incontinence after ablation of the ovaries in dogs. Theriogenology 2003; 60: 1207-1216.
18. Reichler I, Jochle W, Piche C, Roos M, Arnold S. Effect of a long acting GnRH analogue or placebo on plasma LH/FSH, urethral pressure profiles and clinical signs of urinary incompetence due to Sphincter mechanism incompetence in bitches. Theriogenology 2006; 66: 1227-1236.
19. Reichler I, Welle M, Sattler U, Jochle W, Roos M, Hubler M, Barth A, Arnold S. Comparative quantitative assessment of GnRH-and LH-receptor mRNA expression in the urinary tract of sexually intact and spayed female dogs. Theriogenology 2007; 67: 1134-1142.
20. Coit VA, Dowell FJ, Evans NP. Neutering affects mRNA expression levels for the LH- and GnRH-receptors in the canine urinary bladder. Theriogenology 2009; 71: 239-247.
21. Weesner G, Becker B, Matter R. Expression of luteinizing hormone-releasing hormone and its receptor in porcine immune tissues. Life Sci 1997; 61: 1643-1649.
22. Wang L, Xie L-P, Huang W-Q, Yao B, Pu R-L, Zhang R-Q. Presence of gonadotropin-releasing hormone (GnRH) and its mRNA in rat pancreas. Mol Cell Endocrinol 2001; 172: 185-191.
23. Kakar S, Jennes L. Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. Cancer Lett 1995; 98: 57-62.
24. Lee CY, Ho J, Chow SN, Yasojima K, Schwab C, McGeer PL. Immunoidentification of gonadotropin releasing hormone receptor in human sperm, pituitary and cancer cells. Am J Reprod Immunol 2000; 44: 170-177.
25. Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci 2005; 88: 5-28.
26. 2+and protein kinase C. Front Neuroendocrinol 1998; 19: 1-19.
27. Grafer CM, Thomas R, Lambrakos L, Montoya I, White S, Halvorson LM. GnRH stimulates expression of PACAP in the pituitary gonadotropes via both the PKA and PKC signaling systems. Mol Endocrinol 2009; 23: 1022-1032.
28. Mutiara S, Kanasaki H, Oride A, Purwana IN, Shimasaki S, Yamamoto H, Miyazaki K. Follistatin gene expression by gonadotropin-releasing hormone: a role for cyclic AMP and mitogen-activated protein kinase signaling pathways in clonal gonadotroph LbetaT2 cells. Mol Cell Endocrinol 2009; 307: 125-132.
29. Winters S, Ghooray D, Fujii Y, Moore J, Nevitt J, Kakar S. Transcriptional regulation of follistatin expression by GnRH in mouse gonadotroph cell lines: evidence for a role for cAMP signaling Mol Cell Endocrinol. 2007; 271: 45-54.
30. Wu TJ, Glucksman MJ, Roberts JL, Mani SK. Facilitation of lordosis in rats by a metabolite of luteinizing hormone releasing hormone. Endocrinology 2006; 147: 2544-2549.
31. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 2002; 41: 485-504.
32. Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC. An eight-month clinical study of LA-2575 30.0mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003; 62: 319-323.
33. Thorne R, Horn JP. Role of ganglionic cotransmission in sympathetic control of the isolated bullfrog aorta. J Physiol 1997; 498: 201-214.
34. Hasegawa J, Saitoh M, Hirai S, Fukuki M, Kotake H, Yoshida A, Shigemasa C, Mashiba H. Effect of luteinizing hormone-releasing hormone on the mechanical activity of the guinea-pig cardiac muscle. Gen Pharmacol 1989; 20: 743-746.
35. Nakanishi H, Kondo S, Fuji T. Pressor action of luteinizing hormone-releasing hormone in the rat. Jpn J Pharmacol 1981; 31: 852-855.
36. Lee CH, VanAntwerp D, Hedley L, Nestor JJ Jr, Vickery BH. Comparative studies on the hypotensive effect of LHRH antagonists in anesthetized rats. Life Sci 1989; 45: 697-702.
37. Hydock DS, Lien CY, Schneider CM, Hayward R. Effects of voluntary wheel running on cardiac function and myosin heavy chain in chemically gonadectomized rats. Am J Physiol Heart Circ Physiol 2007; 293: H3254-H3264.
38. Hydock DS, Wonders KY, Schneider CM, Hayward R. Androgen deprivation therapy and cardiac function: effects of endurance training. Prostate Cancer Prostatic Dis 2006; 9: 392-398.
39. Wojniusz S, Vogele C, Ropstad E, Evans N, Robinson J, Sutterlin S, Erhard HW, Solbakk AK, Endestad T, Olberg DE, Haraldsen IR. Prepubertal gonadotropin-releasing hormone analog leads to exaggerated behavioral and emotional sex differences in sheep. Horm Behav. 2011; 59: 22-27.
40. Jurgensen H, Christensen N, Ladefoged S, Micic S. Lack of effect on intravenous LHRH on plasma noradrenaline in man. Clin Endocrinol (Oxf) 1980; 13: 249-252.
41. Evans I, Distiller L. Effects of luteinizing hormone-releasing hormone on sexual arousal in normal men. Arch Sex Behav 1979; 8: 385-395.
42. Garnick M, Pratt C, Campion M, Shipley J. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol 2004; 22: 4578.
43. Eckstein N, Pines A, Fisman E, Fisch B, Limor R, Vagman I, Barnan R, Ayalon D. The effect of the hypoestrogenic state, induced by gonadotropin-releasing hormone agonist, on doppler-derived parameters of aortic flow. J Clin Endocrinol Metab 1993; 77: 910-912.
44. Matthews K, Berga S, Owens J, Flory J. Effects of short-term supression of ovarian hormones on cardiovascular and neuroendocrine reactivity to stress in women. Psychoneuroendocrinology 1998; 23: 307-322.
45. Van Gerpen JA, McKinley KL. Leuprolide-induced myopathy. J Am Geriatr Soc 2002; 50: 1746.
46. Coli S, Magnoni M, Melisurgo G, Persico P, Doldi N, De Cobelli F, Del Maschio A, Cianflone D, Maseri A. Myocardial infarction complicating the initial phase of an ovarian stimulation protocol. Int J Cardiol 2007; 115: e56-e57.
47. McCoy MJ. Angina and myocardial infarction with use of leuprolide acetate. Am J Obstet Gynecol 1994; 171: 275-276.
48. Isachenkov V, Bakalkin G, Yarygin K, Komissarova E, Tsibezov V, Trushina E, Badosov E. Cardiotropic effects of luliberin: effects of luliberin on the activities of phosphorylase A and ornithine decarboxylase and concentration of 3', 5'-AMP. Biokhimiia 1979; 44: 233-239.
49. Chen LT, Yao Q, Soares TA, Squier TC, Bigelow DJ. Phospholamban modulates the functional coupling between nucleotide domains in Ca-ATPase oligomeric complexes in cardiac sarcoplasmic reticulum. Biochemistry 2009; 48: 2411-2421.
50. 1 subunit. J Biochem 1996; 120: 170-176.
51. Jia W, Shaffer JF, Harris SP, Leary JA. Identification of novel protein kinase A phosphorylation sites in the M-domain of human and murine cardiac myosin binding protein-C using mass spectrometry analysis. J Proteome Res 2010; 9: 1843-1853.
52. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000; 101: 365-376.
53. Tsai PS, Zhang L. The emergence and loss of gonadotropin-releasing hormone in protostomes: orthology, phylogeny, structure, and function. Biol Reprod 2008; 79: 798-805.
54. Iwakoshi-Ukena E, Ukena K, Takuwa-Kuroda K, Kanda A, Tsutsui K, Minakata H. Expression and distribution of octopus gonadotropin-releasing hormone in the central nervous system and peripheral organs of the octopus (Octopus vulgaris) by in situ hybridization and immunohistochemistry. J Comp Neurol 2004; 477: 310-323.
55. Kanda A, Takahashi T, Satake H, Minakata H. Molecular and functional characterization of a novel gonadotropin-releasing-hormone receptor isolated from the common octopus (Octopus vulgaris). Biochem J 2006; 395: 125-135.
56. Iwakoshi E, Hisada M, Minakata H. Cardioactive peptides isolated from the brain of a Japanese octopus, Octopus minor. Peptides 2000; 21: 623-630.
57. Minakata H, Shigeno S, Kano N, Haraguchi S, Osugi T, Tsutsui K. Octopus gonadotrophin-releasing hormone: a multifunctional peptide in the endocrine and nervous systems of the cephalopod. J Neuroendocrinol 2009; 21: 322-326.
58. Blomenrohr M, ter Laak T, Kuhne R, Beyermann M, Hund E, Bogerd J, Leurs R. Chimaeric gonadotropin-releasing hormone (GnRH) peptides with improved affinity for the catfish (Clarias gariepinus) GnRH receptor. Biochem J 2002; 361: 515-523.
59. Okubo K, Suetake H, Aida K. Expression of two gonadotropin-releasing hormone (GnRH) precursor genes in various tissues of the Japanese eel and evolution of GnRH. Zool Sci 1999; 16: 471-478.
60. Gonzalez-Martinez D, Sarasquete C, Pascual E, Munoz-Cueto JA. Expression of gonadotrophin-releasing hormone binding sites in somatic tissues of the gilthead seabream (Sparus aurata): a quantitative autoradiographic study. Histol Histopathol 2006; 21: 1065-1073.
61. Jodo A, Ando H, Urano A. Five different types of putative GnRH receptor gene are expressed in the brain of masu salmon (Oncorhynchus masou). Zoolog Sci 2003; 20: 1117-1125.
62. Bogerd J, Diepenbroek WB, Hund E, van Oosterhout F, Teves AC, Leurs R, Blomenrohr M. Two gonadotropin-releasing hormone receptors in the African catfish: no differences in ligand selectivity, but differences in tissue distribution. Endocrinology 2002; 143: 4673-4682.
63. 3H) luteinizing hormone-releasing hormone to mice and rats. Neuroendocrinology 1974; 16: 65-73.
64. Heber D, Marshall J, Odell W. GnRH membrane binding: identification, specificity, and quantification in nonpituitary tissues. Am J Physiol 1978; 235: E227-E230.
65. Chu NI, Chan RL, Hama KM, Chaplin MD. Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. Drug Metab Dispos 1985; 13: 560-565.
66. 3H-labeled gonadotropin-releasing hormone analog buserelin in rats. Drug Metab Dispos 1993; 21: 818-822.
67. Dolinska B, Ryszka F, Suszka-Switek A. Distribution and pharmacokinetics of the gonadotropin releasing hormone analogue (GnRH analogue) dalarelin in rats. Boll Chim Farm 2000; 139: 222-224.
68. Schwahn M, Schupke H, Gasparic A, Krone D, Peter G, Hempel R, Kronbach T, Locher M, Jahn W, Engel J. Disposition and metabolism of cetrorelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and dogs. Drug Metab Dispos 2000; 28: 10-20.
69. Chalmers JA, Lin SY, Martino TA, Arab S, Liu P, Husain M, Sole MJ, Belsham DD. Diurnal profiling of neuroendocrine genes in murine heart, and shift in proopiomelanocortin gene expression with pressure-overload cardiac hypertrophy. J Mol Endocrinol 2008; 41: 117-124.
70. Tieva A, Stattin P, Wikstrom P, A B, Damber JE. Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 2001; 47: 276-284.
71. LifeSpan-Biosciences. Gonadotropin-releasing hormone receptor (GnRHR) LSID 1925, Antibody 1925-LP209. 2002: 55.
72. Sharpe R. Extra-pituitary actions of LHRH and its agonists. Nature 1980; 286: 12-14.